MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
MannKind Corporation (MNKD) has scheduled its Q1 2025 financial results announcement for May 8, 2025, before market open.
Rhea-AI Summary
MannKind Corporation (MNKD) has scheduled its Q1 2025 financial results announcement for May 8, 2025, before market open. The company will host a webcast at 9:00 a.m. Eastern Time featuring CEO Michael Castagna and CFO Chris Prentiss to discuss the quarterly results and provide a business update. The webcast will be available through MannKind's investor relations website, with a replay accessible for approximately 90 days following the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – MNKD
The recorded move for MNKD in the trading session of this news was +1.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025.
MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
For MannKind: Investor Relations Ana Kapor (818) 661-5000 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.